Merck & Co., Inc. (MRK)
NYSE · Healthcare · Drug Manufacturers - General
Profile
Merck & Co., Inc.
- Exchange
- NYSE
- Ticker
- MRK
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Key facts
Merck & Co., Inc.: key facts
- Merck & Co., Inc. (NYSE: MRK) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Merck & Co., Inc. reported revenue of $64.9B and net income of $18.3B.
- Revenue grew 7.5% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $67.3B and net income was $2.5B.
MonkScore
Merck & Co., Inc.'s MonkScore
MonkScore
MonkScore range: 60–70
as of October 2026
Sector rank: 266 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth10–20
- Profitability50–60
- Quality50–60
- Market Conviction90–100
- Safety70–80
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Merck & Co., Inc.'s annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $67.3B | $64.9B | $64.2B | $60.1B | $59.3B | $48.7B |
| Gross profit | $51.8B | $46.7B | $49.0B | $44.0B | $41.9B | $35.1B |
| Operating income | $10.9B | $23.5B | $20.2B | $3.0B | $18.3B | $13.2B |
| Net income | $2.5B | $18.3B | $17.1B | $365.0M | $14.5B | $13.0B |
| Operating cash flow | $20.0B | $16.5B | $21.5B | $13.0B | $19.1B | $14.1B |
| Capital expenditure | -$3.9B | -$4.1B | -$3.4B | -$3.9B | -$4.4B | -$4.4B |
| Free cash flow | $16.1B | $12.4B | $18.1B | $9.1B | $14.7B | $9.7B |
| Total debt | $53.9B | $50.5B | $38.3B | $36.3B | $32.0B | $34.6B |
| Cash | $6.8B | $14.6B | $13.2B | $6.8B | $12.7B | $8.1B |
Revenue growth a year
- 1-year
- 1.2%
- 3-year
- 3.1%
- 4-year
- 7.5%
Compound growth between fiscal years.
Peers
Similar companies
- Organon & Co.NYSE:OGNMonkScore range: 60–70
- Johnson & JohnsonNYSE:JNJMonkScore range: 70–80
- Bristol-Myers Squibb CompanyNYSE:BMYMonkScore range: 80–90
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.